Mereo BioPharma Group plc

Equities

MREO

US5894921072

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 09:49:41 2024-07-17 EDT 5-day change 1st Jan Change
4.025 USD -1.59% Intraday chart for Mereo BioPharma Group plc +6.10% +73.16%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday But End Week Higher MT
European Equities Traded in the US as American Depositary Receipts Move Higher in Thursday Trading MT
Leerink Partners Adjusts Price Target on Mereo BioPharma Group to $8 From $6, Maintains Outperform Rating MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading MT
Bank Stocks Help Nudge European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading MT
European Equities Close Lower Friday to End Rough Week of Trading MT
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading MT
Mereo BioPharma Prices $50 Million Offering MT
European Equities Traded in the US as American Depositary Receipts Sharply Lower in Thursday Trading MT
Baird Initiates Mereo BioPharma Group With Outperform Rating, $8 Price Target MT
Sector Update: Health Care Stocks Ease Late Afternoon MT
Sector Update: Health Care MT
Ultragenyx, Mereo BioPharma Shares Rise as Bone Disorder Drug Shows Reduced Fracture Rate MT
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading MT
Sector Update: Health Care Stocks Rise Premarket Wednesday MT
Sector Update: Health Care MT
Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc Announce Positive 14-Month Results from the Phase 2 Portion of the Ongoing Phase 2/3 Orbit Study CI
Ultragenyx, Mereo BioPharma Say Phase 2 Study of Bone Disorder Drug Showed Reduced Fracture Rate MT
European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading MT
Chart Mereo BioPharma Group plc
More charts
Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.157 GBP
Average target price
5.656 GBP
Spread / Average Target
+79.15%
Consensus
  1. Stock Market
  2. Equities
  3. MREO Stock
  4. News Mereo BioPharma Group plc
  5. Sector Update: Health Care Stocks Rise Premarket Wednesday